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Abstract. Syndecan-1 has been shown to be a prognostic factor
in various types of tumors, suggesting its correlation with
malignancy and metastasis. In the present study, we examined
the expression of syndecan-1 in oral cancer cell lines and tested
whether transfection of an siRNA against human syndecan-1
affected the malignant potential of these cells. Seven different
human oral cancer cell lines (HSC2, HSC3, HSC4, Ca9-22,
SAS, KB and BSC-OF) were used. To evaluate the mRNA
expression of syndecan-1 in these cell lines, quantitative real-
time RT-PCR (QRT-PCR) was carried out. In order to examine
syndecan-1 function, siRNA was transfected into the cells, after
which the cell growth rate and invasive ability were evaluated.
As a negative control, a random sequence siRNA was used.
QRT-PCR showed that syndecan-1 was expressed in Ca9-22
cells and that it was significantly higher (>10-fold) than in the
other oral cancer cell lines. Transfection of syndecan-1 siRNA
was carried out on Ca9-22 cells, which increased their growth
rate 1.4-fold above controls. The invasive ability of Ca9-22
cells treated with syndecan-1 siRNA was significantly higher
(2-fold; n=5) than the controls. These results suggest that
Ca9-22 oral cancer cells are a useful model to study syndecan-1
function and they show that syndecan-1 directly contributes to
the growth and invasive ability of these cells.
Introduction
Oral cancer is the fifth most common type of cancer in the
world. Despite modern intervention, the 5-year survival rate
for this disease has improved only marginally over the past
decade (1) and recurrent disease is observed in 50% of patients
(2,3). Survival curves of oral cancer patients have plateaued
over the past 2 decades and remain among the worst of all
cancer sites. Therefore, recent studies in this field have focused
on the development of biomarkers for early detection, disease
monitoring and determining the prognosis of patients with oral
cancer (4,5).
Cell surface adhesion receptors bind cells to the extra-
cellular matrix (ECM) and couple such interactions with
intercellular signaling mechanisms (6). It is apparent that
alterations in cell adhesion can influence almost every stage
of cellular transformation. The development of malignant
epithelial neoplasms is associated with the disruption of cell-
to-cell and cell-to-matrix adhesion (7,8). Syndecans are a
family of heparan sulphate proteoglycan receptors that
participate both in cell-to-cell and in cell-to-matrix adhesion
(9). The syndecan family is composed of four closely related
proteins (syndecans-1 to 4) which are encoded by four different
genes (9). Syndecan-1 binds cells via its heparan sulphate
chains to a variety of components of the interstitial matrix,
including types I, III and V collagen, fibrillar collagen (10),
fibronectin (11) and tenascin (11). Earlier studies noted that
syndecan-1 levels correlate with malignancy in various
tissues including the uterine cervix (12,13) and the esophagus
(14). Studies on syndecan-1 expression in head and neck
carcinomas have suggested that reduced expression of
syndecan-1 is associated with the prognosis of these
neoplasms (15,16). Ro et al (17) reported that a reduction of
syndecan-1 expression correlated with tumor size and
invasion in squamous cell carcinomas of the tongue.
However, expression levels and function(s) of syndecan-1 in
oral cancers remain unknown. In the present study, we
examined syndecan-1 expression in a number of oral cancer
cell lines and used the siRNA approach to characterize the
function(s) of syndecan-1 in these cells.
Materials and methods
Cell cultures. Human oral squamous cell carcinoma (SCC) cell
lines, HSC2, HSC3, HSC4, SAS and KB, were obtained from
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the Japanese Cancer Research Resources Bank (JCRB).
BSC-OF was established from an oral basaloid squamous cell
carcinoma by Abiko et al (18). All cell lines were grown in
Dulbecco's modified Eagle medium (DMEM) or in DMEM/
F-12 (Invitrogen, Grand Island, NY, USA) containing 10%
fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and
penicillin-streptomycin (100 U/ml, Invitrogen) at 37˚C in a
humidified incubator containing 5% CO2.
RNA isolation and quantitative real-time RT-PCR (QRT-PCR).
Total RNA was extracted using the acid guanidinium-
thiocyanate-phenol-chloroform (AGPC) method with TRIzol
(Invitrogen) and cDNA synthesis was performed as described
in our previous study (19). QRT-PCR was carried out using
SYBR-Green and AmpliTaq Gold DNA polymerase (PE
Applied Biosystems, Foster City, CA, USA) according to
our previous study (19). Primers for human syndecan-1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were
used; the sequences of the primers are shown in Table I.
Amplification was then performed in duplicate using the
primer sets in an ABI PRISM 7700 Sequence Detector (PE
Applied Biosystems) with denaturation for 10 min at 95˚C,
followed by 40 PCR cycles of denaturation at 95˚C for 15 sec
and annealing or extension at 60˚C for 1 min. The threshold
cycle (Ct) value for each reaction was calculated and the
relative quantitation (ΔΔCt method) was carried out as
described in our previous studies (19,20). The amplified
products were analyzed by 1.7% agarose gel electrophoresis
and were visualized by ultraviolet illumination after staining
with ethidium bromide.
Immunofluorescence. Cells were cultured on cover glasses and
then were fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer (PB). The specimens were washed in phosphate-
buffered saline (PBS) and were blocked in 10% normal goat
serum. They were then incubated with anti-human syndecan-1
antibody (1:500, Dako, Copenhagen, Denmark) at room
temperature for 60 min. After washing in PBS, Alexa488-
conjugated anti-mouse IgG (Molecular Probes, Eugene, OR,
USA) was used as a secondary antibody and the specimens
were observed using a fluorescence microscope (Axiophot2,
Zeiss, Oberkochen, Germany).
siRNA transfection. In order to knock down syndecan-1
function in the cells, an siRNA insert of syndecan-1 was
designed using a website named siRNA Target Finder
(Ambion, Austin, TX, USA). Since the siRNA target
sequence of syndecan-1 was 5'-AACTTCTCCGGCTCAGG
TGCA-3', synthetic top strand oligonucleotide templates of
the insert for syndecan-1 siRNA: 5'-CTTCTCCGGCTCAG
GTGCATTCAAGAGATGCACCTGAGCCGGAGAAGTT
TTTT-3' and the bottom strand oligonucleotide template:
5'-AATTAAAAAACTTCTCCGGCTCAGGTGCATCTCT
TGAATGCACCTGAGCCGGAGAAGGGCC-3' were
incubated with annealing buffer (TEN buffer: 10 mM Tris-HCl,
1 mM EDTA, pH 7.6 and 100 mM NaCl) at 95˚C for 5 min,
then cooled to 37˚C and incubated for 1 h at 37˚C. Synthetic
oligonucleotides of syndecan-1 were inserted into the ApaI
and EcoRI sites of the pSilencer™ 1.0-U6 vector (Ambion).
The plasmid and pSilencer 1.0 Negative Control (Ambion)
were transfected into the cells using the lipofection method
(Effecten™, Qiagen, Hilden, Germany) according to the
manufacturer's protocol. Decreased expression of syndecan-1
in the cells was confirmed by RT-PCR.
Cell growth rate. The cells were seeded at 1.0x105 cells/ml
into 35-mm plates. The cells were detached using 0.25%
trypsin every 24 h and were counted using a Coulter Counter
(Beckman Coulter, Fullerton, CA, USA). Results were
analyzed and growth curves were plotted.
Invasion assay. The invasion assay was carried out according
to our previous studies (19,21). Aliquots of 1x105 cells were
plated onto 6-well BioCoat™ Matrigel™ Invasion Chambers
(BD Biosciences, San Jose, CA, USA) and were cultured
for 24 h. Cells digested the Matrigel, enabling them to pass
through the micro-pores in the gel, after which they were fixed
and stained. The numbers of invasive cells were counted
using a light microscope per 1 mm2 in the central area of the
Matrigel. The assays were repeated three times and results are
shown as mean ± SD.
Results
Expression of syndecan-1 mRNA in human oral carcinoma cell
lines. To validate the high expression levels of syndecan-1 in
human oral cancer cell lines, QRT-PCR was carried out. Based
on the ΔΔCt relative to KB cells, the relative expression
levels of syndecan-1 mRNA in oral carcinoma cell lines were
calculated. Several cell lines showed expression of syndecan-1
at high levels. In particular, syndecan-1 was expressed in
Ca9-22 cells at a higher level (13.2-fold) than in KB cells
(Fig. 1A). Moreover, relatively higher expression levels of
syndecan-1 were seen in BSC-OF and in HSC3 cells (7.6-fold).
Immunofluorescence analysis showed that positive
reactions for syndecan-1 were observed strongly at the cell
membrane of Ca9-22 cells (Fig. 1B) while diffuse faint dot
reactions were seen in KB cells (Fig. 1C). Based on those
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Table I. Sequences of primers used in this study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Primer sequences Product size
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Syndecan-1 F: 5'-AGGACGAAGGCAGCTACT CCT-3' 71 bp
R: 5'-TTTGGTGGGCTTCTGGTAGG-3'
GAPDH F: 5'-GTCATGGGTGTGAACCATGAGAA-3' 136 bp
R: 5'-TGGTCATGAGTCCTTCCACGAT-3'
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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QRT-PCR and immunofluorescence results, we used Ca9-22
cells as a model for high expression of syndecan-1 in this
study.
Effects of human syndecan-1 siRNA. In order to characterize
the effects of syndecan-1 siRNA, we carried out QRT-PCR
analysis using mRNAs from non-transfected (control) and
from transfected Ca9-22 cells. After 48 h of incorporation,
decreased expression (1/10-fold) of syndecan-1 was seen in
the siRNA-transfected cells, suggesting that siRNA blocked
syndecan-1 expression very efficiently in Ca9-22 cells
(Fig. 2A). Electrophoretic analysis confirmed that a decline
of syndecan-1 was observed in transfected Ca9-22 cells
(Fig. 2B).
Cell growth. To examine whether syndecan-1 is associated
with cell growth, the growth of siRNA-transfected cells and
control cells was measured. Ca9-22 cells had increased
growth after syndecan-1 siRNA transfection. The numbers
of siRNA-transfected Ca9-22 cells and control cells at 48 h
were 6.0±0.4x105 and 4.1±0.3x105 (average ± SD),
respectively and at 72 h were 11.8±1.4x105 and 8.1±0.5x105,
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Figure 1. Expression of human syndecan-1 in oral carcinoma cells. (A)
QRT-PCR analysis shows that syndecan-1 is expressed in Ca9-22 cells at a
higher level (13.2-fold) than in KB cells. Moreover, a relatively higher
expression level of syndecan-1 is seen in BSC-OF cells and in HSC3 cells
(7.6-fold). The ΔΔCt relative to KB cells is considered as 1. (B and C)
Immunofluorecence analysis shows that positive reactions for syndecan-1
are strongly observed at the cell membrane of Ca9-22 cells (B) while diffuse
faint dot reactions are seen in KB cells (C).
Figure 2. Efficiency of human syndecan-1 siRNA. (A) In order to characterize
the effects of syndecan-1 siRNA, QRT-PCR analysis was performed on
mRNAs from non-transfected (control) and from siRNA-transfected Ca9-22
cells. After 48 h incorporation, decreased expression (1/10-fold) of syndecan-1
was seen in the siRNA-transfected cells, suggesting that siRNA blocks
syndecan-1 expression very efficiently in Ca9-22 cells. (B) Electrophoresis
analysis confirming a decline in syndecan-1 in siRNA-transfected Ca9-22
cells.
Figure 3. Cell growth rates. Ca9-22 cells transfected with syndecan-1 siRNA
had increased growth. The growth rate of control cells was lower than the
siRNA-treated cells at 48 and at 72 h. The growth rates were significantly
different between the siRNA and the control groups at 48 and at 72 h (p<0.01).
Figure 4. Invasion assay. The Matrigel assay was used to investigate the
effects of syndecan-1 on the invasive ability of Ca9-22 cells. The number of
invading cells was significantly higher in the siRNA-transfected group
(p<0.01).
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respectively. The cell growth rate of control cells was
lower than the siRNA-transfected cells at 48 and at 72 h
(Fig. 3) and were significantly different at both time points
(p<0.01). 
Invasion assay. To examine the effect of syndecan-1 on the
invasive ability of Ca9-22 cells, a Matrigel assay was used.
The numbers of invasive siRNA-transfected and control
Ca9-22 cells were 718.4±64.7 per mm2 and 378.8±102.1 per
mm2 (average ± SD), respectively, which was significantly
higher (p<0.01) (Fig. 4).
Discussion
Syndecan-1 has been reported to be a prognostic factor for
tumor progression and survival in various types of malignant
tumors, which suggests a close correlation of syndecan-1
expression with malignancy and metastasis (16,22). In general,
transformed cells are often characterized by an abundant
secretion of syndecan-1, which results in metastasis formation
(23,24). Earlier studies associated syndecan-1 levels with
prognosis and have suggested syndecan-1 as a candidate
biomarker for the malignant potential of head and neck tumors
(16). Our earlier study showed that syndecan-1 contributed
to their malignant behavior including changes in growth
and invasive ability (17). However, expression levels and
function(s) of syndecan-1 in oral cancers have not been
clarified, and therefore, we examined that in this study using
siRNA to block syndecan-1 functions. Our results show that
three oral cancer cell lines, Ca9-22, BSC-OF and HSC3,
express syndecan-1 at high levels compared to KB cells.
Ca9-22 cells are therefore a useful model for elucidating the
function of syndecan-1 in oral cancers. Furthermore, our
results show that the siRNA used in this study is specific
and is effective for blocking syndecan-1 expression and thus
will be helpful for analyzing the function(s) of syndecan-1 in
oral cancer cells.
Our previous study showed that the reduction of immuno-
reactivity for syndecan-1 in oral squamous cell carcinoma cells
was associated with tumor size, suggesting that syndecan-1
contributes to malignant behavior including changes in
growth and invasive ability. Recent studies have shown that a
reduction of syndecan-1 expression was associated with
proliferative activity (Ki-67 expression) (25). Furthermore,
Su et al reported that shedding of syndecan-1 by stromal
fibroblasts stimulated the proliferation of human breast cancer
cells via activation of FGF2 (26). Our results show that the
reduction of syndecan-1 function by siRNA leads to higher
levels of cell proliferation, which suggests that syndecan-1 is
directly associated with cell proliferation.
Cell migration has been reported to influence invasiveness
and to be an important factor in the incidence of metastasis.
Moreover, the invasive ability of tumors is closely related to
the incidence of metastasis and the prognosis of the disease.
As shown in previous studies, reduced expression of
syndecan-1 correlates with metastasis of various tumors.
There have been only a few studies that showed a correlation
between syndecan-1 and invasion in oral cancers, but there has
been no previous functional study of syndecan-1 using an oral
cancer cell line. Therefore, we examined whether syndecan-1
was associated with the invasive ability of Ca9-22 cells. Our
results show that invasiveness increased when syndecan-1
function was blocked in siRNA-transfected Ca9-22 cells. The
expression of syndecan-1 is known to suppress the level of
matrix metalloproteinase (MMP)-9 and to inhibit cell invasion
into type I collagen (27,28). Moreover, syndecan-1 can be
degraded by heparanase (29), and invasion is associated with
MMPs (30) and heparanase activities (31). The syndecan-1
siRNA may induce MMPs and heparanase activity and thus
reduce the expression of syndecan-1 in Ca9-22 cells.
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